CSL Ltd
CSL: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$782.00 | Pdvts | Xnnzfvcx |
CSL Earnings: Strong Performance in CSL Behring
Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The guidance factors in continued gross margin recovery in CSL Behring and constant-currency group revenue growth of 9%-11%, largely driven by immunoglobulins, or Ig. We keep our estimates broadly unchanged and maintain our AUD 310 fair value estimate. Shares remain slightly undervalued.